Drug General Information (ID: DDI6ALFTP4)
Drug Name			Ondansetron		Drug Info		Osilodrostat		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiemetics				Adrenal Corticosteroid Inhibitors
Structure

Mechanism of Ondansetron-Osilodrostat Interaction (Severity Level: Moderate)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Ondansetron				Osilodrostat
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Ondansetron and Osilodrostat

Recommended Action
Management		Caution is recommended if osilodrostat is used in combination with other drugs that can prolong the QT interval. An electrocardiogram and serum electrolyte levels should be obtained prior to initiating osilodrostat therapy and periodically thereafter. Correct hypokalemia and/or hypomagnesemia before starting treatment and as indicated during treatment, as they may be risk factors for ventricular arrhythmias.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.